205 related articles for article (PubMed ID: 9815771)
21. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
22. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
Vasey PA; Jones NA; Jenkins S; Dive C; Brown R
Mol Pharmacol; 1996 Dec; 50(6):1536-40. PubMed ID: 8967975
[TBL] [Abstract][Full Text] [Related]
24. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
25. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
26. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
27. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.
Ganly I; Kim YT; Hann B; Balmain A; Brown R
Gene Ther; 2001 Mar; 8(5):369-75. PubMed ID: 11313813
[TBL] [Abstract][Full Text] [Related]
28. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
29. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
30. p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma.
Oggionni M; Pilotti S; Suardi S; Ditto A; Luoni C; Mariani L; Scambia G; Fanfani F; Zunino F
Oncology; 2005; 69(2):154-8. PubMed ID: 16127286
[TBL] [Abstract][Full Text] [Related]
31. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
32. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
33. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells.
Cvijic ME; Chin KV
Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205
[TBL] [Abstract][Full Text] [Related]
34. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins.
Roy G; Horton JK; Roy R; Denning T; Mitra S; Boldogh I
Oncogene; 2000 Jan; 19(1):141-50. PubMed ID: 10644989
[TBL] [Abstract][Full Text] [Related]
35. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
Langton-Webster BC; Xuan JA; Brink JR; Salomon DS
Cell Growth Differ; 1994 Dec; 5(12):1367-72. PubMed ID: 7696185
[TBL] [Abstract][Full Text] [Related]
36. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
38. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
39. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Griffith TS; Kemp TJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
[TBL] [Abstract][Full Text] [Related]
40. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin.
Cemazar M; Sersa G; Miklavcic D
Anticancer Res; 1998; 18(6A):4463-6. PubMed ID: 9891510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
